1.1
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs fo…
Drug discovery is the process by which new drug candidates are identified to treat or prevent diseases.
Drug discovery involves various stages: target identification, hits identification, lead generation and optimization, and drug candidate identification.
First, molecular targets of the drugs, such as receptors, enzymes, and other functional proteins and nucleic acids, are identified using biochemical assays, genetic interactions, and computational methods.
The next step is identifying hit, molecules that bind to the selected biological target. To do so, libraries of thousands of compounds, chemically synthesized or natural products, are screened using high-throughput assays.
Hits that pass the primary screening are modified to generate leads that show pharmacological activity against the chosen target.
These leads are optimized by combinatorial chemistry to improve their potency and target selectivity and reduce adverse effects. They are also tested for their pharmacokinetics and bioavailability.
Such screening identifies a few drug candidates that are further tested for clinical applications.
View the full transcript and gain access to JoVE Core videos
Q1: What are the main stages of drug discovery?
Drug discovery involves four key stages: target identification, hits identification, lead generation and optimization, and drug candidate identification. First, molecular targets like receptors and enzymes are identified using biochemical assays and computational methods. Next, high-throughput screening identifies hit molecules that bind to the target. Leads are then generated and optimized for potency, selectivity, and reduced adverse effects before final drug candidates are selected.
Q2: How are molecular targets identified in drug discovery?
Molecular targets such as receptors, enzymes, and functional proteins are identified using biochemical assays, genetic interactions, and computational methods. These targets are the specific biological molecules that drugs will interact with to produce therapeutic effects. Identifying the correct target is the critical first step in drug discovery, as it guides all subsequent screening and optimization efforts.
Q3: What is the purpose of high-throughput screening in drug discovery?
High-throughput screening evaluates thousands of chemically synthesized compounds or natural products to identify hits—molecules that bind to the selected biological target. This rapid screening process narrows down vast compound libraries to a manageable number of promising candidates. Hits that pass primary screening are then modified to generate leads showing pharmacological activity against the chosen target.
Q4: How are lead compounds optimized during drug discovery?
Lead compounds are optimized through combinatorial chemistry to improve potency, target selectivity, and reduce adverse effects. Leads undergo testing for pharmacokinetics and bioavailability to ensure they work effectively in the body. Animal studies assess the compound's activity in vivo, potential adverse effects, and oral availability. Only compounds meeting these criteria advance to preclinical development.
Q5: What testing methods determine a drug candidate's pharmacological profile?
Drug candidates are tested at multiple levels: molecular assays like receptor binding assays evaluate target interaction; cell function studies determine whether the drug acts as an agonist, antagonist, or inverse agonist; and whole animal studies assess effects on organ systems and disease models. These comprehensive tests identify lead compounds with desired pharmacological activity and selectivity for further development.
Q6: Why do most drug discovery projects fail to produce a successful drug candidate?
Many factors hinder progress in drug discovery, including the inability to optimize lead compounds or failure to produce desired effects in animal models. Lead optimization is time-consuming and challenging, with only a small percentage of projects succeeding. Compounds must demonstrate efficacy, safety, and appropriate pharmacokinetic properties across multiple testing phases before advancing to clinical trials.
Q7: What distinguishes hits from leads in the drug discovery process?
Hits are initial molecules identified through high-throughput screening that bind to the biological target. Leads are hits that have been chemically modified to show pharmacological activity against the target. Leads represent a more advanced stage, having demonstrated functional effects beyond simple binding, and serve as the basis for further chemical modification and optimization.